The U.S. Food and Drug Administration approved Gilead Sciences Inc.’s drug for treating chronic hepatitis C virus infection.
U.S. Senate Democrats called for bipartisan talks in the funding fight over Zika, saying a Republican proposal was “extreme and insufficient” to combat the virus and was full of “ideological poison pill riders.”
Smartphones, social media and crowdsourcing all have the potential to help people get faster, better treatment for heart attacks and strokes, according to the American Heart Association (AHA).
It’s official – Waltham, Massachusetts-based FORUM Pharmaceuticals will be shuttering its doors before the Fourth of July holiday.
Infinity Pharmaceuticals announced that North Chicago-based AbbVie chose to terminate its collaboration deal to develop and commercialize duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which are associated with malignant B-cells.
Australian company Mayne Pharma is acquiring 37 approved drugs and five products that have been filed with the U.S. FDA from Teva Pharmaceutical Industries and Allergan.
Pfizer Inc. will invest $350 million to build a biotech center in China, the latest in a series of moves by pharma industry giants to set up shop in the world’s no. 2 drugs market.
The U.S. Supreme Court rejected a bid to review a legal fight over the cancellation of a patent on a less-risky form of prenatal testing, in a case that has left many companies and trade groups worried that important discoveries may no longer qualify for patents.
After announcing that its Phase III clinical trial for algenpantucel-KL for resected pancreatic cancer failed in May, Ames, Iowa-based NewLink Genetics confirmed that it has laid off 87 employees.
AnGes MG Inc. announced its decision to amend the global development strategy of HGF Plasmid (AMG0001, Beperminogene Perplasmid) for the treatment of critical limb ischemia.